Curative Biotechnology Inc (CUBT) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $0.92 (-17.12%), Market cap $0.01B, 52-week low–high $0.65 ~ $2.25.
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative
Financial statements, price targets, institutional (13F) holdings and related news for Curative Biotechnology Inc are updated in real time on BlackAll Trade.
Curative Biotechnology Inc trades at $0.92 (-17.12%). Real-time quotes and charts are available on BlackAll Trade.
Curative Biotechnology Inc has a market cap of about $0.01B.
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformul